nivolumab | Nivolumab

Keyword	CPC	PCC	Volume	Score	Length of keyword
nivolumab	1.61	0.6	9902	18	9

Keyword	CPC	PCC	Volume	Score
nivolumab	1.68	0.5	2712	10
nivolumab melanoma	1.02	0.8	7802	15
nivolumab side effects	0.91	0.3	7010	40
nivolumab immunotherapy	1.91	0.5	5142	53
nivolumab package insert	0.37	0.6	3462	26
nivolumab moa	1.38	0.4	2993	44
nivolumab mechanism of action	0.67	1	5261	87
nivolumab and ipilimumab	0.13	0.3	8669	11
nivolumab and pembrolizumab	1.4	0.4	360	69
nivolumab opdivo	1.46	0.1	1470	75
nivolumab relatlimab	1.5	0.9	5823	24
nivolumab brand name	1.46	0.9	9059	35
nivolumab cost per dose	1.49	0.5	8866	89
nivolumab fda	1.53	0.6	2625	98
nivolumab spc	0.3	0.1	8926	80
nivolumab ema	1.24	1	7815	98
nivolumab smpc	0.88	0.2	9999	89
nivolumab nsclc	0.84	0.7	7808	64
nivolumab and pembrolizumab combination	0.23	0.8	9933	41
nivolumab and pembrolizumab for melanoma	0.09	0.1	6729	34
nivolumab injection	1.92	0.4	7939	10
nivolumab side effects uptodate	0.13	0.3	7902	37
nivolumab rcp	0.44	1	8352	59
nivolumab and pembrolizumab side effects	0.73	0.7	9986	28
nivolumab biosimilar	1.11	0.8	6086	82

Search Results related to nivolumab on Search Engine

Nivolumab - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Nivolumab

WebNivolumab is the second FDA-approved systemic therapy for mesothelioma [15] and is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer. [11] Medical uses. In the US, nivolumab is indicated to treat: Unresectable or Metastatic Melanoma [9] Adjuvant Treatment of Melanoma [9] Metastatic Non-Small Cell Lung Cancer [9]

DA: 100 PA: 2 MOZ Rank: 88

Nivolumab - NCI - National Cancer Institute
cancer.gov

https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab

WebNivolumab is a type of targeted therapy drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system.

DA: 2 PA: 41 MOZ Rank: 56

Nivolumab : Uses, Side Effects, Dosage, Warnings - Drugs.com
drugs.com

https://www.drugs.com/nivolumab.html

WebMar 13, 2024 · What is nivolumab? Nivolumab is a cancer medicine that is given intravenously (into a vein) that works with your immune system to interfere with the growth and spread of cancer cells in the body. Nivolumab is used alone or in combination with other medicines to treat adults with: advanced melanoma (a type of skin cancer);

DA: 30 PA: 47 MOZ Rank: 56

Nivolumab (Opdivo) | Cancer information | Cancer Research UK
cancerresearchuk.org

https://www.cancerresearchuk.org/about-cancer/treatment/drugs/nivolumab

WebNivolumab is a type of immunotherapy called a monoclonal antibody. Immunotherapy work by blocking a protein that stops the immune system from working properly and attacking cancer cells. It helps to make your immune system find and kill cancer cells. Find out more about immunotherapy drugs.

DA: 7 PA: 83 MOZ Rank: 84

Nivolumab - StatPearls - NCBI Bookshelf
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK567801/

WebDec 5, 2022 · Follow NCBI. Nivolumab is a medication used to manage and treat metastatic melanoma and several other tumors. It is a monoclonal antibody that targets the anti-PD1 receptor, an immune checkpoint. This activity outlines the indications, mechanism of action, and administration for nivolumab to manage advanced cancers.

DA: 27 PA: 68 MOZ Rank: 67

Nivolumab (Intravenous Route) Description and Brand Names
mayoclinic.org

https://www.mayoclinic.org/drugs-supplements/nivolumab-intravenous-route/description/drg-20127723

WebNivolumab is a monoclonal antibody that affects the immune system and helps control the growth of cancer cells. This medicine is to be given only by or under the supervision of your doctor. This product is available in the following dosage forms:

DA: 28 PA: 70 MOZ Rank: 17

Nivolumab: Uses, Interactions, Mechanism of Action | DrugBank …
drugbank.com

https://go.drugbank.com/drugs/DB09035

WebNivolumab is a PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. Brand Names. Opdivo, Opdualag. Generic Name. Nivolumab. DrugBank Accession Number. DB09035.

DA: 36 PA: 94 MOZ Rank: 58

Nivolumab | Memorial Sloan Kettering Cancer Center
mskcc.org

https://www.mskcc.org/cancer-care/patient-education/medications/adult/nivolumab

WebMonday, December 12, 2022. This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider.

DA: 67 PA: 26 MOZ Rank: 11

FDA approves nivolumab in combination with chemotherapy for …
fda.gov

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-combination-chemotherapy-metastatic-gastric-cancer-and-esophageal

WebOn April 16, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with fluoropyrimidine- and platinum-containing chemotherapy for...

DA: 79 PA: 75 MOZ Rank: 77

Nivolumab Injection: MedlinePlus Drug Information
medlineplus.gov

https://medlineplus.gov/druginfo/meds/a614056.html

WebNivolumab injection is used alone or in combination with ipilimumab (Yervoy) to treat certain types of melanoma (a type of skin cancer) in adults and children 12 years of age or older that has spread to other parts of the body or cannot be removed by surgery. It is also used alone to prevent melanoma from returning after surgery.

DA: 1 PA: 19 MOZ Rank: 28